Imaging predictor of ophthalmic involvement in maxillary sinus cancer during super selective intra-arterial cisplatin infusion and concomitant radiotherapy (RADPLAT)

Hirokazu Ashida,Hideomi Yamauchi,Takao Igarashi,Yosuke Nozawa,Hisashi Kessoku,Hiromi Kojima,Hiroya Ojiri,Yohei Munetomo,Takahiro Higuchi,Akira Baba,Yukio Nishiya,Yukiko Abe,Eiji Shimura

doi:10.1186/s13005-021-00285-z

Hirokazu Ashida, Hideomi Yamauchi + Show 11 more

Open Access

https://doi.org/10.1186/s13005-021-00285-z

Copy DOI

Journal: Head & Face Medicine	Publication Date: Aug 16, 2021
Citations: 3	License type: open-access

Affiliation: Jikei University School of Medicine

Abstract

ObjectiveTo investigate the predictability of ophthalmic artery involvement in maxillary sinus cancer using preprocedural contrast enhanced CT and MRI.MethodsWe analyzed advanced (T3, T4a, and T4b) primary maxillary sinus squamous cell carcinoma treated with super-selective intra-arterial cisplatin infusion and concomitant radiotherapy (RADPLAT) from Oct 2016 to Mar 2020. Two diagnostic radiologists evaluated the tumor invasion site around the maxillary sinus using preprocedural imaging. These results were compared with the angiographic involvement of the ophthalmic artery using statistical analyses. We also evaluated our RADPLAT quality using complication rate, response to treatment, local progressive free survival (LPFS), and overall survival (OS).ResultsTwenty patients were included in this study. There were ten cases of ophthalmic artery tumor stain and there was a correlation between ophthalmic artery involvement and invasion for ethmoid sinus with statistically significant differences. Other imaging findings were not associated with ophthalmic artery involvement.ConclusionsEthmoid sinus invasion on preprocedural imaging could suggest ophthalmic artery involvement in maxillary sinus cancer. It may be useful in predicting prognosis and treatment selection.

Highlights

Maxillary sinus cancer (MSC) is a rare disease in Japan, representing only about 3 % of all head and neck cancers and 0.5 % of all malignant diseases [1]
We described the duration of the post-treatment follow-up period, treatment completion rate, local progression-free survival (LPFS), overall survival (OS), response to treatment according to Response evaluation criteria in solid tumor guideline, dose limiting toxicities according to Common Terminology Criteria for Adverse Events version 5.0, and whether salvage surgery or neck dissection was performed after the RADPLAT
All cases met the inclusion criteria; one case was excluded from the registry according to the exclusion criteria because the ophthalmic artery defect was recognized on preprocedural DCECT (Fig. 1)

Summary

Introduction

Maxillary sinus cancer (MSC) is a rare disease in Japan, representing only about 3 % of all head and neck cancers and 0.5 % of all malignant diseases [1]. Even if the patient is diagnosed with advanced MSC, lymphatic or hematogenic metastasis is less common [4]. Complete resection is performed for these patients. There are, many problems such as impairment of facial function and significant facial deformity after surgical procedures for advanced MSCs [3]. There is no indication of surgical resection for patients with stage T4b MSC. Chemoradiotherapy (CRT) is the standard therapeutic option for Ashida et al Head & Face Medicine (2021) 17:34 unresectable MSCs; the prognosis of these patients is not satisfactory [5]

Methods

Results

Conclusion